Atomoxetine in the treatment of patients with ADHD
Gerbers, J.A.; Allen, A.J.
American Family Physician 71(10): 1879-80; Author Reply 1880 1882
2005
ISSN/ISBN: 0002-838X PMID: 15926406 Document Number: 590552
Document emailed within 1 workday
Related Documents
Resen, K.; Pagsberg, A.K.; Jörgens, G. 2014: Atomoxetine for treatment of children and adolescents with ADHD Ugeskrift for Laeger 176(10a)Clemow, D.B. 2014: Suboptimal dosing of strattera (Atomoxetine) for ADHD patients Postgraduate Medicine 126(5): 196-198
Adler, L.A.; Spencer, T.J.; Williams, D.W.; Moore, R.J.; Michelson, D. 2008: Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study Journal of Attention Disorders 12(3): 248-253
Zavadenko, N.N.; Suvorinova, N.Iu. 2008: Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(7): 43-47
Biederman, J. 2002: Treatment of ADHD Seishin Shinkeigaku Zasshi 104(12): 1147-1159
Breggin, P.R. 2001: Questioning the treatment for ADHD Science 291(5504): 595
Jacobsson, L.; Hägglöf, B. 2015: Reconsider the diagnosis and treatment approach for ADHD Lakartidningen 112
Montano, B. 2004: Diagnosis and treatment of ADHD in adults in primary care Journal of Clinical Psychiatry 65(Suppl 3): 18-21
Thomas, M.; Rostain, A.; Prevatt, F. 2013: ADHD diagnosis and treatment in college students and young adults Adolescent medicine: state of the art reviews 24(3): 659-679
Buitelaar, J.K.; Kooij, J.J. 2000: Attention deficit hyperactivity disorder (ADHD): etiology, diagnosis and treatment Nederlands Tijdschrift Voor Geneeskunde 144(36): 1716-1723
't Jong, G.W.; van den Anker, J.N. 2000: Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment Nederlands Tijdschrift Voor Geneeskunde 144(46): 2227-2228
Roy, M.; Ohlmeier, M.D.; Osterhagen, L.; Prox-Vagedes, V.; Dillo, W. 2013: Asperger Syndrome: a frequent comorbidity in first diagnosed adult ADHD patients? Psychiatria Danubina 25(2): 133-141
Borg Skoglund, L. 2019: ADHD across the lifespan - The need for guidelines for assessment and treatment of neurodevelopmental disorders in an aging population Lakartidningen 116
Zetterström, R. 2002: Central stimulants in the treatment of children with ADHD: unknown long-term effect and uncertain pharmacological documentation Lakartidningen 99(7): 677-680
Mulas, F.; Roca, P.; Ros-Cervera, G.; Gandía-Benetó, R.én.; Ortiz-Sánchez, P. 2014: Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy Revista de Neurologia 58(Suppl 1): S43-S49
Saylor, K.E.; Buermeyer, C.M.; Spencer, T.J.; Barkley, R.A. 2002: Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication Journal of Clinical Psychiatry 63(Suppl 12): 23-28
Sugama, M.; Ishizaki, A. 2014: Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate No to Hattatsu 46(1): 22-25
Thomsen, P.H.; Damm, D. 2008: ADHD in adults Ugeskrift for Laeger 170(43): 3395-3399
Cestari, E.R. 2008: ADHD: risks and dangers Epidemiologia e Prevenzione 32(1): 2
Jacobs, J. 1998: Biases in reporting of ADHD Journal of the American Academy of Child and Adolescent Psychiatry 37(10): 1009-1010